All In Biotech

Drug Trial Radar · NCT05217303

HL-085 in NRAS-mutated Advanced Melanoma

A Single-arm, Multi-center Phase II Clinical Study to Evaluate the Efficacy and Safety of HL-085 in Advanced Melanoma Patients With NRAS Mutation

Last checked: Nov 19, 2026Latest source record: May 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

100

Actual

Start

Nov 2, 2020

Primary completion

Feb 19, 2023

Study completion Feb 20, 2023

Sponsor

Lead sponsor
Shanghai Kechow Pharma, Inc.Industry
Sponsor type
Industry
First posted
Feb 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an open-label, single-arm, multi-center phase II clinical study, aimed at investigating the efficacy and safety of HL-085 capsule in the treatment of advanced melanoma patients with NRAS mutation.

Conditions

  • Melanoma

Interventions

  • HL-085Drug

    HL-085 capsule administered orally twice daily (BID) in a 21-day treatment cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. objective response rate (ORR)Time frame: through study completion, an average of 1 year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Beijing Oncology Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.